Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How CA 125 is used in routine clinical practice.

P Petignat1, F Joris, R Obrist

  • 1Department of Obstetrics and Gynecology, Hôpital de Sion, CH-1950 Sion, Switzerland. ppetignat@hotmail.com

European Journal of Cancer (Oxford, England : 1990)
|September 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of definitive uterine artery occlusion on ovarian reserve markers in laparoscopic myomectomy: a randomized controlled trial with 2-year follow-up.

Human reproduction (Oxford, England)·2025
Same author

[P. Vassilakos and P. Petignat in reply to the article entitled: "Organized cervical screening at last in France!!". Gynecol Obstet Fertil Senol 2019;47:1-2].

Gynecologie, obstetrique, fertilite & senologie·2019
Same author

Accuracy of combinations of visual inspection using acetic acid or lugol iodine to detect cervical precancer: a meta-analysis.

BJOG : an international journal of obstetrics and gynaecology·2017
Same author

Endometriosis after menopause: physiopathology and management of an uncommon condition.

Climacteric : the journal of the International Menopause Society·2017
Same author

Myoma migration: an unexpected "effect" with Ulipristal acetate treatment.

European review for medical and pharmacological sciences·2016
Same author

Stage IVB endometrial cancer: clinical course and survival of patients with single and multiple metastases.

European journal of gynaecological oncology·2015

The CA 125 test is only useful for monitoring ovarian cancer (OC) or preoperative evaluation of ovarian masses. A study found only 33% of CA 125 tests were used appropriately, highlighting a need for better clinical guidance.

Area of Science:

  • Oncology
  • Clinical Chemistry
  • Medical Diagnostics

Background:

  • The CA 125 assay is a biomarker primarily associated with ovarian cancer.
  • Established clinical utility for CA 125 is limited to monitoring ovarian cancer and preoperative assessment of ovarian masses.

Purpose of the Study:

  • To evaluate the appropriateness of CA 125 test indications in clinical practice.
  • To identify patterns of CA 125 test utilization and assess adherence to established guidelines.

Main Methods:

  • Retrospective audit of all CA 125 assays performed at Institut Central des Hôpitaux Valaisans (ICHV) between August 1993 and December 1995.
  • Analysis of patient data to determine the clinical indication for each CA 125 test performed.

Main Results:

Related Experiment Videos

  • Out of 1057 CA 125 assays across 462 patients, only 57% of tests (for 33% of patients) met the criteria for correct indication (OC monitoring or preoperative assessment).
  • A significant proportion of tests (43%) were used for screening in various clinical situations, indicating inappropriate utilization.
  • Specifically, 18% of patients were monitored for OC, and 15% were evaluated preoperatively for ovarian masses.

Conclusions:

  • The study reveals widespread inappropriate use of the CA 125 test in clinical practice.
  • There is a clear need for educational initiatives targeting healthcare providers to promote rational and evidence-based utilization of CA 125 assays.
  • Optimizing CA 125 test ordering can improve diagnostic accuracy and resource allocation in oncology.